Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.68 |
| ▸ | MAOB | P27338 | 9/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945013 | 0.86 | MAOB (0.62) | NR4A2MAOBMAPTPOLBMRGPRX4 | |
| SCHEMBL18161369 | 0.86 | MAOB (0.65) | NR4A2MAOBMAPTPOLBMRGPRX4 | |
| SCHEMBL5669711 | 0.85 | MAOB (0.74) | NR4A2MAOBMAPTPOLBMRGPRX4 | |
| SCHEMBL21945509 | 0.84 | MAOB (0.59) | NR4A2MAOBMAPTPOLBMRGPRX4 | |
| SCHEMBL12879351 | 0.83 | MAOB (0.65) | NR4A2MAOBMAPTPOLBMRGPRX4 | |
| SCHEMBL31172140 | 0.83 | MAOB (0.76) | NR4A2MAOBMAPTPOLBMRGPRX4 | |
| SCHEMBL16710550 | 0.83 | MAOB (0.65) | NR4A2MAOBMAPTPOLBMRGPRX4 | |
| SCHEMBL4640143 | 0.83 | MAOB (0.76) | NR4A2MAOBMAPTPOLBMRGPRX4 | |
| SCHEMBL21945062 | 0.82 | NR4A2 (0.49) | NR4A2MAOBMAPTPOLBMRGPRX4 | |
| SCHEMBL27501493 | 0.82 | MAPT (0.62) | NR4A2MAOBMAPTPOLBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104277051-B | 4 aminothiophenes simultaneously [3,2 C] carboxylic acid derivates of pyridine 7 | 霍夫曼-拉罗奇有限公司 | 2017-06-09 | — | — | CN | disclosed |
| US-9624239-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-04-18 | — | — | US | disclosed |
| US-9624239-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-04-18 | — | — | US | disclosed |
| EP-1926737-B1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-15 | — | — | EP | disclosed |
| EP-1926737-B1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-15 | — | — | EP | disclosed |
| CN-101263145-B | 4-amino-thieno [3,2-C ] pyridine-7-carboxylic acid derivatives | HOFFMANN LA ROCHE | 2015-02-25 | — | — | CN | disclosed |
| CN-104277051-A | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | HOFFMANN LA ROCHE | 2015-01-14 | — | — | CN | disclosed |
| US-20140045833-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045833-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| CN-101263145-A | 4-amino-thieno [3, 2-C ] pyridine-7-carboxylic acid derivatives | HOFFMANN LA ROCHE (CH) | 2008-09-10 | — | — | CN | disclosed |
| EP-1926737-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031428-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031428-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BARTKOVITZ DAVID J | 2007-03-15 | — | — | US | disclosed |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BARTKOVITZ DAVID J | 2007-03-15 | — | — | US | disclosed |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BARTKOVITZ DAVID J | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045833-A1 | Protein Kinase Inhibitors | LCK, BTK, TEC | NR4A2 458/4885MAOB 2938/4885MAPT 3381/4885 |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BRAF, RAF1, MAP3K7 | NR4A2 1933/4885MAOB 1364/4885MAPT 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.